A Phase 3 interventional study of Saxagliptin and Saxagliptin in Diabetes, sponsored by AstraZeneca. Completed at 211 sites in 13 countries. Open to participants aged 18 Years to 77 Years. Per ClinicalTrials.gov, last updated 2015-04-29.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing saxagliptin in Diabetes Mellitus — none open to participants now, none under way, none of them phase 3. saxagliptin · Diabetes Mellitus.
Among the 10 studies testing saxagliptin in Diabetes Mellitus, this one has the largest enrollment, is one of 3 that started in 2006, is one of 4 in phase 3, and was the 3rd registered.
8,294 studies on the registry are indexed under Diabetes Mellitus; 1,072 are open to participants now.
Browse Diabetes Mellitus studies →None of the 10 studies testing saxagliptin in Diabetes Mellitus is open now. The open studies under Diabetes Mellitus, anywhere →
saxagliptin: first FDA approval 2009 (ONGLYZA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 649 Diabetes Mellitus studies recruiting now, 359 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.
This study: 18 Years to 77 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 3 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,306 is above the median of 80 across 6,026 interventional studies indexed under Diabetes Mellitus.
Median enrollment 66 across the 10 interventional studies. Of the 9 that completed or were terminated, 8 (89%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 10 have an industry lead sponsor. The 4 most frequent:
AstraZeneca is the lead sponsor of 3,505 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
122 studies in Diabetes Mellitus by AstraZeneca: none open now, none under way, none of them phase 3. Of 121 finished, 58 (48%) have results posted.
Among the 122 studies in Diabetes Mellitus by AstraZeneca, this one is the 4th largest by enrollment of the 91 interventional ones that give a count, is one of 14 that started in 2006, is one of 49 in phase 3, and was the 26th registered.
AstraZeneca’s Diabetes Mellitus studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 10 studies testing saxagliptin in Diabetes Mellitus, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AstraZeneca’s 122 in Diabetes Mellitus:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this trial is to understand if adding saxagliptin to metformin therapy is safe and works better than taking either saxagliptin or metformin alone
All subjects will participate in a lead-in period, and qualifying subjects will continue into a short-term randomized treatment period. Subjects who complete the short-term period will be eligible to enter the long term extension period. Also, subjects in the short-term period who have an elevated blood sugar that requires additional medication for blood sugar control will be eligible to enter the long-term treatment extension period where they will receive pioglitazone (rescue medication) added onto their blinded study medication
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
PLUS open-label pioglitazone (as needed as rescue medication)
Drug: Saxagliptin · Drug: Metformin · Drug: pioglitazone
PLUS open-label pioglitazone (as needed as rescue medication)
Drug: Saxagliptin · Drug: Metformin · Drug: pioglitazone
PLUS open-label pioglitazone (as needed as rescue medication)
Drug: Saxagliptin · Drug: Placebo · Drug: pioglitazone
PLUS open-label pioglitazone (as needed as rescue medication)
Drug: Metformin · Drug: Placebo · Drug: pioglitazone
Coated Tablets, Oral, 10 mg, Daily (6 months ST, 12 months LT)
Also known as: BMS-477118
Coated tablets, PO, 5 mg, Daily (6 months ST, 12 months LT)
Also known as: BMS-477118
Coated tablets, Oral, 500 mg, Daily (6 months ST, 12 months LT)
Coated tablets, Oral, 0 mg, Daily (6 months ST, 12 months LT)
Tablets, Oral, 15-45 mg, as needed (12 months LT)
Change From Baseline in Hemoglobin A1c (A1C) at Week 24, Saxagliptin Plus Metformin Versus Saxagliptin Monotherapy
Mean change from baseline in A1C at Week 24, adjusted for baseline value.
Time frame: Baseline, Week 24
Change From Baseline in A1C at Week 24, Saxagliptin Plus Metformin Versus Metformin Monotherapy
Mean change from baseline in A1C at Week 24, adjusted for baseline value.
Time frame: Baseline, Week 24
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24, Saxagliptin Plus Metformin Versus Saxagliptin Monotherapy
Mean change from baseline in FPG at Week 24, adjusted for baseline value.
Time frame: Baseline, Week 24
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24, Saxagliptin Plus Metformin Versus Metformin Monotherapy
Mean change from baseline in FPG at Week 24, adjusted for baseline value.
Time frame: Baseline, Week 24
Percentage of Participants Achieving A1C < 7% at Week 24, Saxagliptin Plus Metformin Versus Saxagliptin Monotherapy
Percentage of participants achieving A1C \< 7%, the American Diabetes Association's defined goal for glycemia, at each dose of saxagliptin plus metformin versus saxagliptin alone at Week 24.
Time frame: Week 24
Percentage of Participants Achieving A1C < 7% at Week 24, Saxagliptin Plus Metformin Versus Metformin Monotherapy
Percentage of participants achieving A1C \< 7%, the American Diabetes Association's defined goal for glycemia, at each dose of saxagliptin plus metformin versus metformin alone at Week 24.
Time frame: Week 24
Changes From Baseline in Postprandial Glucose (PPG) Area Under the Curve (AUC) Response to an Oral Glucose Tolerance Test (OGTT) at Week 24, Saxagliptin Plus Metformin Versus Saxagliptin Monotherapy
Mean change from baseline for 0 to 180 minutes PPG AUC at Week 24, adjusted for baseline value.
Time frame: Baseline, Week 24
Changes From Baseline in Postprandial Glucose (PPG) Area Under the Curve (AUC) Response to an Oral Glucose Tolerance Test (OGTT) at Week 24, Saxagliptin Plus Metformin Versus Metformin Monotherapy
Mean change from baseline for 0 to 180 minutes PPG AUC at Week 24, adjsuted for baseline value.
Time frame: Baseline, Week 24
Percentage of Participants Achieving A1C ≤6.5% at Week 24, Saxagliptin Plus Metformin Versus Saxagliptin Monotherapy
Percentage of participants achieving A1C ≤6.5%, at each dose of saxagliptin plus metformin versus saxagliptin alone at Week 24.
Time frame: Week 24
Percentage of Participants Achieving A1C ≤6.5% at Week 24, Saxagliptin Plus Metformin Versus Metformin Monotherapy
Percentage of participants achieving A1C ≤6.5%, at each dose of saxagliptin plus metformin versus metformin alone at Week 24.
Time frame: Week 24
Percentage of Participants Requiring Rescue or Discontinuation at Week 24, Saxagliptin Plus Metformin Versus Saxagliptin Monotherapy
Percentage of participants requiring rescue for failing to achieve pre-specified glycemic targets or discontinuing for lack of efficacy within the 24-week treatment period at each dose of saxagliptin plus metformin versus saxagliptin alone.
Time frame: Week 24
Percentage of Participants Requiring Rescue or Discontinuation at Week 24, Saxagliptin Plus Metformin Versus Metformin Monotherapy
Percentage of participants requiring rescue for failing to achieve pre-specified glycemic targets or discontinuing for lack of efficacy within the 24-week treatment period at each dose of saxagliptin plus metformin versus metformin alone.
Time frame: Week 24
| Milestone | Saxagliptin 5 mg + Metformin | Saxagliptin 10 mg + Metformin | Saxagliptin 10 mg | Metformin |
|---|---|---|---|---|
| Started | 320 | 323 | 335 | 328 |
| Completed study without being rescued | 179 | 177 | 113 | 144 |
| Completed | 229 | 231 | 209 | 219 |
| Not completed | 91 | 92 | 126 | 109 |
| Withdrew: Lack of efficacy | 18 | 18 | 35 | 29 |
| Withdrew: Withdrawal of consent by subject | 20 | 24 | 28 | 25 |
| Withdrew: Lost to follow-up | 22 | 23 | 29 | 22 |
| Withdrew: Adverse event | 14 | 10 | 14 | 14 |
| Withdrew: Subject no longer meets study criteria | 4 | 2 | 8 | 7 |
| Withdrew: Poor/noncompliance | 11 | 8 | 4 | 5 |
| Withdrew: Physician decision | 0 | 1 | 3 | 2 |
| Withdrew: Death | 1 | 2 | 2 | 3 |
| Withdrew: Pregnancy | 0 | 2 | 1 | 1 |
| Withdrew: Administrative reason by sponsor | 1 | 2 | 2 | 1 |
Mean change from baseline in A1C at Week 24, adjusted for baseline value.
| percent | Saxagliptin 5 mg + Metformin | Saxagliptin 10 mg + Metformin | Saxagliptin 10 mg |
|---|---|---|---|
| Baseline Mean | 9.41 ± 0.072 | 9.53 ± 0.069 | 9.61 ± 0.075 |
| Week 24 Mean | 6.93 ± 0.066 | 7.02 ± 0.067 | 7.86 ± 0.085 |
| Adjusted Mean Change from Baseline | -2.53 ± 0.070 | -2.49 ± 0.069 | -1.69 ± 0.069 |
Mean change from baseline in FPG at Week 24, adjusted for baseline value.
| mg/dL | Saxagliptin 5 mg + Metformin | Saxagliptin 10 mg + Metformin | Saxagliptin 10 mg |
|---|---|---|---|
| Baseline Mean | 198.9 ± 3.17 | 204.3 ± 3.35 | 200.9 ± 3.03 |
| Week 24 Mean | 140.2 ± 2.39 | 140.1 ± 2.34 | 169.9 ± 3.20 |
| Adjusted Mean Change from Baseline | -59.8 ± 2.34 | -62.2 ± 2.34 | -30.9 ± 2.30 |
Mean change from baseline in FPG at Week 24, adjusted for baseline value.
| mg/dL | Saxagliptin 5 mg + Metformin | Saxagliptin 10 mg + Metformin | Metformin |
|---|---|---|---|
| Baseline Mean | 198.9 ± 3.17 | 204.3 ± 3.35 | 199.1 ± 3.28 |
| Week 24 Mean | 140.2 ± 2.39 | 140.1 ± 2.34 | 152.7 ± 2.80 |
| Adjusted Mean Change from Baseline | -59.8 ± 2.34 | -62.2 ± 2.34 | -47.3 ± 2.33 |
Percentage of participants achieving A1C \< 7%, the American Diabetes Association's defined goal for glycemia, at each dose of saxagliptin plus metformin versus saxagliptin alone at Week 24.
| Percentage of participants | Saxagliptin 5 mg + Metformin | Saxagliptin 10 mg + Metformin | Saxagliptin 10 mg |
|---|---|---|---|
| Percentage of Participants Achieving A1C < 7% at Week 24, Saxagliptin Plus Metformin Versus Saxagliptin Monotherapy | 60.3 | 59.7 | 32.2 |
Percentage of participants achieving A1C \< 7%, the American Diabetes Association's defined goal for glycemia, at each dose of saxagliptin plus metformin versus metformin alone at Week 24.
| Percentage of participants | Saxagliptin 5 mg + Metformin | Saxagliptin 10 mg + Metformin | Metformin |
|---|---|---|---|
| Percentage of Participants Achieving A1C < 7% at Week 24, Saxagliptin Plus Metformin Versus Metformin Monotherapy | 60.3 | 59.7 | 41.1 |
Mean change from baseline for 0 to 180 minutes PPG AUC at Week 24, adjusted for baseline value.
| mg*min/dL | Saxagliptin 5 mg + Metformin | Saxagliptin 10 mg + Metformin | Saxagliptin 10 mg |
|---|---|---|---|
| Baseline Mean | 55531 ± 1116.5 | 57219 ± 1169.6 | 57584 ± 1143.4 |
| Week 24 Mean | 35324 ± 890.0 | 35790 ± 888.9 | 41229 ± 1050.9 |
| Adjusted Mean Change from Baseline | -21080 ± 836.5 | -21336 ± 869.6 | -16054 ± 826.7 |
Mean change from baseline in A1C at Week 24, adjusted for baseline value.
| percent | Saxagliptin 5 mg + Metformin | Saxagliptin 10 mg + Metformin | Metformin |
|---|---|---|---|
| Baseline Mean | 9.41 ± 0.072 | 9.53 ± 0.069 | 9.43 ± 0.073 |
| Week 24 Mean | 6.93 ± 0.066 | 7.02 ± 0.067 | 7.48 ± 0.084 |
| Adjusted Mean Change from Baseline | -2.53 ± 0.070 | -2.49 ± 0.069 | -1.99 ± 0.069 |
Mean change from baseline for 0 to 180 minutes PPG AUC at Week 24, adjsuted for baseline value.
| mg*min/dL | Saxagliptin 5 mg + Metformin | Saxagliptin 10 mg + Metformin | Metformin |
|---|---|---|---|
| Baseline Mean | 55531 ± 1116.5 | 57219 ± 1169.6 | 57937 ± 1281.7 |
| Week 24 Mean | 35324 ± 890.0 | 35790 ± 888.9 | 42428 ± 1082.1 |
| Adjusted Mean Change from Baseline | -21080 ± 836.5 | -21336 ± 869.6 | -15005 ± 857.0 |
Percentage of participants achieving A1C ≤6.5%, at each dose of saxagliptin plus metformin versus saxagliptin alone at Week 24.
| Percentage of Participants | Saxagliptin 5 mg + Metformin | Saxagliptin 10 mg + Metformin | Saxagliptin 10 mg |
|---|---|---|---|
| Percentage of Participants Achieving A1C ≤6.5% at Week 24, Saxagliptin Plus Metformin Versus Saxagliptin Monotherapy | 45.3 | 40.6 | 20.3 |
Percentage of participants achieving A1C ≤6.5%, at each dose of saxagliptin plus metformin versus metformin alone at Week 24.
| Percentage of participants | Saxagliptin 5 mg + Metformin | Saxagliptin 10 mg + Metformin | Metformin |
|---|---|---|---|
| Percentage of Participants Achieving A1C ≤6.5% at Week 24, Saxagliptin Plus Metformin Versus Metformin Monotherapy | 45.3 | 40.6 | 29.0 |
Percentage of participants requiring rescue for failing to achieve pre-specified glycemic targets or discontinuing for lack of efficacy within the 24-week treatment period at each dose of saxagliptin plus metformin versus saxagliptin alone.
| Percentage of participants | Saxagliptin 5 mg + Metformin | Saxagliptin 10 mg + Metformin | Saxagliptin 10 mg |
|---|---|---|---|
| Percentage of Participants Requiring Rescue or Discontinuation at Week 24, Saxagliptin Plus Metformin Versus Saxagliptin Monotherapy | 7.5 | 5.9 | 21.2 |
Percentage of participants requiring rescue for failing to achieve pre-specified glycemic targets or discontinuing for lack of efficacy within the 24-week treatment period at each dose of saxagliptin plus metformin versus metformin alone.
| Percentage of participants | Saxagliptin 5 mg + Metformin | Saxagliptin 10 mg + Metformin | Metformin |
|---|---|---|---|
| Percentage of Participants Requiring Rescue or Discontinuation at Week 24, Saxagliptin Plus Metformin Versus Metformin Monotherapy | 7.5 | 5.9 | 10.1 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Metformin | — | 15/328 (4.6%) | 106/328 (32.3%) |
| Saxagliptin 10 mg | — | 16/335 (4.8%) | 106/335 (31.6%) |
| Saxagliptin 10 mg + Metformin | — | 22/323 (6.8%) | 122/323 (37.8%) |
| Saxagliptin 5 mg + Metformin | — | 16/320 (5%) | 116/320 (36.3%) |
| Event | Metformin | Saxagliptin 10 mg | Saxagliptin 10 mg + Metformin | Saxagliptin 5 mg + Metformin |
|---|---|---|---|---|
| MYOCARDIAL INFARCTIONCardiac disorders | 0/328 | 0/335 | 2/323 | 0/320 |
| CARDIAC FAILURECardiac disorders | 2/328 | 0/335 | 0/323 | 0/320 |
| ATRIAL FIBRILLATIONCardiac disorders | 2/328 | 0/335 | 1/323 | 1/320 |
| ACUTE MYOCARDIAL INFARCTIONCardiac disorders | 2/328 | 0/335 | 0/323 | 1/320 |
| CORONARY ARTERY DISEASECardiac disorders | 0/328 | 0/335 | 0/323 | 1/320 |
| CHOLECYSTITISHepatobiliary disorders | 0/328 | 0/335 | 0/323 | 1/320 |
| CEREBRAL INFARCTIONNervous system disorders | 0/328 | 0/335 | 0/323 | 1/320 |
| FACIAL NERVE DISORDERNervous system disorders | 0/328 | 0/335 | 0/323 | 1/320 |
| GASTRITISGastrointestinal disorders | 0/328 | 0/335 | 1/323 | 1/320 |
| HIATUS HERNIAGastrointestinal disorders | 0/328 | 0/335 | 0/323 | 1/320 |
| Event | Metformin | Saxagliptin 10 mg | Saxagliptin 10 mg + Metformin | Saxagliptin 5 mg + Metformin |
|---|---|---|---|---|
| DIARRHOEAGastrointestinal disorders | 30/328 | 12/335 | 41/323 | 26/320 |
| HEADACHENervous system disorders | 18/328 | 31/335 | 36/323 | 31/320 |
| NASOPHARYNGITISInfections and infestations | 19/328 | 24/335 | 19/323 | 29/320 |
| HYPERTENSIONVascular disorders | 17/328 | 19/335 | 21/323 | 27/320 |
| URINARY TRACT INFECTIONInfections and infestations | 25/328 | 23/335 | 22/323 | 13/320 |
| INFLUENZAInfections and infestations | 19/328 | 17/335 | 13/323 | 20/320 |
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 10/328 | 14/335 | 19/323 | 15/320 |
| Age, Continuous(years) | Saxagliptin 5 mg + Metformin | Saxagliptin 10 mg + Metformin | Saxagliptin 10 mg | Metformin | Total |
|---|---|---|---|---|---|
| Mean | 51.95 ± 10.43 | 52.08 ± 11.59 | 52.09 ± 10.17 | 51.83 ± 10.74 | 51.99 ± 10.73 |
| Sex: Female, Male(Participants) | Saxagliptin 5 mg + Metformin | Saxagliptin 10 mg + Metformin | Saxagliptin 10 mg | Metformin | Total |
|---|---|---|---|---|---|
| Female | 155 | 177 | 166 | 165 | 663 |
| Male | 165 | 146 | 169 | 163 | 643 |
Showing the first 100 of 211 sites across 13 countries. Choose a country and city above to see the rest.
The record gives a start of May 2006, a primary completion of Nov 2007 and a completion of Dec 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2009, 1 year 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Saxagliptin · Metformin